Tiotropium + Formoterol More Effective than Ipratropium + Salbutamol in COPD
calendar
18 Mar, 14

Tiotropium + Formoterol is More Effective than Ipratropium + Salbutamol in COPD

Objective

  • To compare the bronchodilator response of a single dose of Tiotropium + Formoterol (Duova; Cipla Ltd., India) pressurized metered dose inhaler (pMDI) with four doses of Ipratropium + Salbutamol administered via dry powder inhaler (Rotahaler; Cipla Ltd., India) in moderate-to-severe COPD patients.

Patients and Methods

  • Randomized, double-blind, cross-over study.
  • 18 moderate to severe COPD patients.
  • Patients received a single dose of Tiotropium + Formoterol (18/12 mcg) or four doses of Ipratropium + Salbutamol (20/100 mcg) on two separate days, at least three days apart.

Results

  • A single dose of Tiotropium + Formoterol produced an equivalent bronchodilator response as four doses of Ipratropium + Salbutamol as measured by AUC0-24 hrs for FEV1 (p = 0.79) and for FVC (p = 0.59).
Mean % change in FEV1 from baseline for 2 treatments over a period of 24hours

  • Trough FEV1, FVC values were significantly higher with single dose of Tiotropium + Formoterol as compared to Ipratropium + Salbutamol.

Conclusion

  • Once daily Tiotropium + Formoterol pMDI produces an equivalent bronchodilation response as four times a day of Ipratropium + Salbutamol.
  • Trough FEV1 and FVC values are superior with Tiotropium + Formoterol pMDI.

P3496, presented at European Respiratory Society (ERS) Conference, 2008